DK2928495T3 - Sammensætninger, der omfatter anti-cd38-antistoffer og lenalidomid - Google Patents

Sammensætninger, der omfatter anti-cd38-antistoffer og lenalidomid Download PDF

Info

Publication number
DK2928495T3
DK2928495T3 DK13861470.6T DK13861470T DK2928495T3 DK 2928495 T3 DK2928495 T3 DK 2928495T3 DK 13861470 T DK13861470 T DK 13861470T DK 2928495 T3 DK2928495 T3 DK 2928495T3
Authority
DK
Denmark
Prior art keywords
lenalidomid
antibodies
compositions concerning
concerning anti
compositions
Prior art date
Application number
DK13861470.6T
Other languages
Danish (da)
English (en)
Inventor
Blake Tomkinson
Byron C Hann
Iii Thomas G Martin
Blake T Aftab
Original Assignee
Sanofi Sa
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Univ California filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK2928495T3 publication Critical patent/DK2928495T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK13861470.6T 2012-12-07 2013-12-06 Sammensætninger, der omfatter anti-cd38-antistoffer og lenalidomid DK2928495T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734524P 2012-12-07 2012-12-07
US201361769247P 2013-02-26 2013-02-26
US201361808372P 2013-04-04 2013-04-04
PCT/US2013/073540 WO2014089416A1 (en) 2012-12-07 2013-12-06 Compositions comprising anti-cd38 antibodies and lenalidomide

Publications (1)

Publication Number Publication Date
DK2928495T3 true DK2928495T3 (da) 2019-06-24

Family

ID=50884019

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13861470.6T DK2928495T3 (da) 2012-12-07 2013-12-06 Sammensætninger, der omfatter anti-cd38-antistoffer og lenalidomid

Country Status (31)

Country Link
EP (2) EP3597191A1 (OSRAM)
JP (2) JP6499971B2 (OSRAM)
KR (2) KR102193045B1 (OSRAM)
CN (1) CN105263520B (OSRAM)
AR (1) AR093844A1 (OSRAM)
AU (2) AU2013355064B2 (OSRAM)
BR (1) BR112015012987A2 (OSRAM)
CA (1) CA2893946A1 (OSRAM)
CL (2) CL2015001558A1 (OSRAM)
CY (2) CY1122478T1 (OSRAM)
DK (1) DK2928495T3 (OSRAM)
ES (1) ES2731548T3 (OSRAM)
HR (1) HRP20191034T1 (OSRAM)
HU (3) HUE044142T2 (OSRAM)
IL (2) IL239234B (OSRAM)
LT (2) LT2928495T (OSRAM)
LU (1) LUC00187I2 (OSRAM)
MX (2) MX366296B (OSRAM)
MY (1) MY191601A (OSRAM)
NL (1) NL301079I2 (OSRAM)
NZ (1) NZ709215A (OSRAM)
PH (1) PH12015501263A1 (OSRAM)
PL (1) PL2928495T3 (OSRAM)
PT (1) PT2928495T (OSRAM)
RS (1) RS58829B1 (OSRAM)
RU (1) RU2698911C2 (OSRAM)
SG (3) SG10201704536PA (OSRAM)
SI (1) SI2928495T1 (OSRAM)
TW (2) TW201919699A (OSRAM)
UA (1) UA118255C2 (OSRAM)
WO (1) WO2014089416A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
WO2016022589A2 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
NZ777133A (en) 2015-06-22 2025-05-02 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
RS61651B1 (sr) 2015-11-03 2021-04-29 Janssen Biotech Inc Potkožne formulacije anti-cd38 antitela i njihova upotreba
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN109689690B (zh) 2016-07-15 2023-10-03 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
CA3088199A1 (en) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
KR102286498B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드의 경구용 코팅 정제 조성물
JP2021518424A (ja) * 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 様々な用量のレナリドミドの経口用錠剤組成物
KR102286499B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
MX2020012286A (es) 2018-05-16 2021-04-28 Janssen Biotech Inc Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
KR20210069642A (ko) * 2018-10-01 2021-06-11 셀진 코포레이션 암 치료를 위한 병용 요법
MX2021011181A (es) * 2019-03-15 2022-01-19 Morphosys Ag Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos.
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
WO2020250033A1 (en) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
IL292181A (en) * 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
AU2020397170A1 (en) 2019-12-05 2022-07-21 Sanofi-Aventis U.S. Llc Formulations of anti-CD38 antibodies for subcutaneous administration
US20250277051A1 (en) * 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN101084252B (zh) * 2004-12-21 2012-06-13 日本化药株式会社 环氧树脂、环氧树脂组合物及其固化物
MX2007011064A (es) * 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
NZ576122A (en) * 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
ES2617446T3 (es) 2010-09-27 2017-06-19 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38

Also Published As

Publication number Publication date
MX2015007189A (es) 2016-03-21
PT2928495T (pt) 2019-07-04
AU2013355064A1 (en) 2015-07-09
JP2019070020A (ja) 2019-05-09
CY2020040I1 (el) 2021-03-12
LTC2928495I2 (lt) 2024-11-25
EP2928495A1 (en) 2015-10-14
IL239234B (en) 2021-05-31
LTPA2020537I1 (lt) 2020-12-28
SG11201504315WA (en) 2015-07-30
EP2928495B1 (en) 2019-03-27
PL2928495T3 (pl) 2019-09-30
SG10201704536PA (en) 2017-07-28
KR102193045B1 (ko) 2020-12-18
CL2015001558A1 (es) 2015-10-02
IL282542A (en) 2021-06-30
MX366296B (es) 2019-07-04
LT2928495T (lt) 2019-07-10
RU2015127089A (ru) 2017-01-13
JP6499971B2 (ja) 2019-04-10
CY2020040I2 (el) 2021-05-05
EP3597191A1 (en) 2020-01-22
HRP20191034T1 (hr) 2019-08-23
ES2731548T3 (es) 2019-11-15
SI2928495T1 (sl) 2019-07-31
JP2016506388A (ja) 2016-03-03
EP2928495A4 (en) 2016-05-11
RS58829B1 (sr) 2019-07-31
AU2018211258A1 (en) 2018-08-16
CY1122478T1 (el) 2021-01-27
HK1215536A1 (en) 2016-09-02
AU2013355064B2 (en) 2018-05-24
MX2019008065A (es) 2019-09-23
IL239234A0 (en) 2015-07-30
AR093844A1 (es) 2015-06-24
RU2698911C2 (ru) 2019-09-02
CL2018003292A1 (es) 2019-02-01
KR20150091165A (ko) 2015-08-07
SG10201913783PA (en) 2020-03-30
MY191601A (en) 2022-07-01
CN105263520A (zh) 2016-01-20
TW201919699A (zh) 2019-06-01
HUE044142T2 (hu) 2019-09-30
HUS2000051I1 (hu) 2020-12-28
HUS2000050I1 (hu) 2020-12-28
PH12015501263A1 (en) 2015-08-17
CN105263520B (zh) 2020-03-13
CA2893946A1 (en) 2014-06-12
TWI670062B (zh) 2019-09-01
WO2014089416A1 (en) 2014-06-12
UA118255C2 (uk) 2018-12-26
NL301079I2 (nl) 2021-03-29
TW201427663A (zh) 2014-07-16
KR20200143503A (ko) 2020-12-23
LUC00187I2 (OSRAM) 2024-07-01
BR112015012987A2 (pt) 2017-09-12
NZ709215A (en) 2020-08-28

Similar Documents

Publication Publication Date Title
CY2024011I2 (el) Αντισωματα anti-fcrn
LTC2928495I2 (lt) Kompozicijos, apimančios anti-cd38 antikūnus ir lenalidomidą
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
IL243752B (en) Multispecific antibodies, preparations containing them and their uses
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
EP3488847C0 (en) SEMIFLUORINATED ALKANE COMPOSITIONS
DK2934584T3 (da) Anti-gdf15-antistoffer
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
HUE053439T2 (hu) Sejtes immunterápiára szolgáló eljárás és készítmények
BR112014030278A2 (pt) anticorpo, e, composição.
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
DK3117837T3 (da) Antistofformuleringer
BR112015002738A2 (pt) composto , e , composição farmacêutica
EP2934454C0 (en) Anti-dandruff composition
BR112014032798A2 (pt) composição
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK2935330T3 (da) Anti-notch3-antistoffer
DK2805954T3 (da) 7-substitueret hanfangichin b-derivat, og fremstillingsfremgangsmåde og anvendelse deraf
BR112014032712A2 (pt) composição
HUE049445T2 (hu) Új kompozíciók
EP2837670A4 (en) Fluorobiphenyl-containing composition
EP2900693A4 (en) ADCC-mediating antibodies, combinations and uses thereof